Abiopharma

New Form 6-K - Burning Rock Biotech Ltd Filed: 2025-09-08 AccNo: 0001193125-25-197601 Size: 225 KB

New Form SCHEDULE 13G/A - PolyPid Ltd. Filed: 2025-09-08 AccNo: 0001178913-25-003266 Size: 16 KB

New Form EFFECT - MEI Pharma, Inc. Filed: 2025-09-05 AccNo: 9999999995-25-002851 Size: 1 KB

New Form EFFECT - Tivic Health Systems, Inc. Filed: 2025-09-05 AccNo: 9999999995-25-002853 Size: 1 KB

New Form EFFECT - Rein Therapeutics, Inc. Filed: 2025-09-05 AccNo: 9999999995-25-002855 Size: 1 KB

New Form QUALIF - Regen BioPharma Inc Filed: 2025-09-05 AccNo: 9999999994-25-000175 Size: 1 KB

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma

Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

General Announcement: Update on investigations into Former Group CEO Dr Shao Yongxin in relation to whistleblowing reports

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT 2016

IFF expands LMR Naturals site in Grasse, advancing naturals innovation leadership

FDA approve METOPROLOL TARTRATE

FDA approve PAZOPANIB HYDROCHLORIDE

FDA approve PALIPERIDONE

Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025